Product Categories

Bcr-Abl

Bcr-Abl Inhibitors (14)

water-soluble

Cat.No. Product Name Information Product Citations Customer Reviews
S1490 Ponatinib (AP24534) AP24534 is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.
S1026 Imatinib Mesylate Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.
S1033 Nilotinib (AMN-107) Nilotinib (AMN-107, Tasigna) is a Bcr-Abl inhibitor with IC50 less than 30 nM.
S2243 WP1130 WP1130 (degrasyn) is a selective deubiquitinase (DUB) inhibitor and also inhibits Bcr/Abl with IC50 of 1.8 μM.
S1369 Bafetinib (INNO-406) Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM and 19 nM, respectively.
S1021 Dasatinib (BMS-354825) Dasatinib (BMS-354825, Sprycel) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of ＜1 nM, 0.5 nM and 79 nM, respectively.
S1006 Saracatinib (AZD0530) Saracatinib (AZD0530) is a Src inhibitor for c-Src and v-Abl with IC50 of 2.7 nM and 30 nM, respectively.
S5002 Fingolimod (FTY720) FTY720 (Fingolimod, Gilenya) is a S1P antagonist with IC50 of 0.033 nM.
S1107 Danusertib (PHA-739358) Danusertib (PHA-739358) is an Aurora inhibitor for Aurora A/B/C, Bcr-Abl, c-RET and FGFR with IC50 of 13 nM/79 nM/61 nM, 25 nM, 31 nM and 47 nM, respectively.
S1134 AT9283 AT9283 is a potent pan-Aurora inhibitor for Aurora A, Aurora B, JAK3, JAK2 and Abl with IC50 of 3 nM, 3 nM, 1.1 nM, 1.2 nM and 4 nM, respectively.
Cat.No. Product Name Information Product Citations Customer Reviews
S2158 KW 2449 KW-2449 potently inhibits Flt3, Abl and Aurora A with IC50 of 6.6 nM, 14 nM and 48 nM, respectively.
S2202 NVP-BHG712 NVP-BHG712 is a specific inhibitor of c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM and also inhibits EphB4 and VEGFR2 with ED50 of 25 nM and 4.2 μM, respectively.
S2634 DCC-2036 (Rebastinib) DCC-2036 is a conformational control inhibitor of Abl1 and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, respectively.
S2899 GNF-2 GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, inhibiting the proliferation of the Bcr-Abl-expressing cells with IC50 of 138 nM.
Page:
  • 1
  • 2
All Bcr-Abl Inhibitors
Tags: Abl activation | Abl kinase domain | Abl activity | Bcr-Abl fusion protein | Abl kinase domain mutation | Bcr-Abl pathway | Bcr-Abl drug | Bcr-Abl assay | Bcr-Abl inhibitor cancer | Bcr-Abl inhibitor in vivo | Bcr-Abl inhibitor review